Bravecto (Fluralaner)

Fluralaner, the active ingredient in Bravecto, blocks arthropod GABA‑ and glutamate‑gated chloride channels. This disruption causes uncontrolled neuronal firing in fleas and ticks, leading to paralysis and death while sparing the host’s nervous system.

The dose of Bravecto is determined by the animal’s weight and prescribed by a veterinarian. The product is supplied in chewable tablets calibrated for specific weight ranges, and the prescriber selects the appropriate tablet for each patient.

Safety data for Bravecto in pregnant or lactating dogs and cats are limited. Veterinarians should weigh the benefits against potential risks and may recommend alternative control measures if there are concerns.

To order Bravecto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Bravecto’s long‑acting isoxazoline formulation provides up to 12 weeks of protection with a single oral dose, whereas many alternative products require monthly administration. Its mechanism targets chloride channels, differing from older insecticides that act on acetylcholinesterase or nicotinic receptors.

Bravecto should be stored at room temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. This helps maintain the stability of the chewable tablet until the expiration date.

Bravecto is given orally as a chewable tablet. The tablet should be offered as a treat or mixed with food, ensuring the animal consumes the entire dose. Administration is typically performed by the pet owner or a veterinary professional.

Serious adverse events, though rare, include seizures, severe allergic reactions such as anaphylaxis, and significant hepatic disturbances. Owners should monitor pets for neurological signs or systemic reactions and seek veterinary care promptly if they occur.

Bravecto should not be used in puppies younger than eight weeks, in animals with a known hypersensitivity to fluralaner or other isoxazolines, and in pets with a history of seizures unless a veterinarian determines the benefits outweigh the risks.